Benign Prostatic Hyperplasia: Rapid Evidence Review

Area of Science:

• Urology
• Men's Health
• Pharmacology

Background:

• Lower urinary tract symptoms (LUTS) due to benign prostatic hyperplasia (BPH) affect 25% of US men, with significant symptom burden in half.
• Risk factors for LUTS include sedentary lifestyle, hypertension, and diabetes mellitus.
• Accurate prostate evaluation is crucial for effective BPH management.

Purpose of the Study:

• To review current diagnostic and therapeutic strategies for LUTS in BPH.
• To highlight the role of patient-reported outcomes and self-management.
• To discuss the efficacy of various medical and surgical interventions.

Main Methods:

• Literature review of diagnostic tools for prostate evaluation.
• Analysis of evidence for self-management techniques and herbal remedies.
• Evaluation of pharmacological treatments including alpha blockers, PDE-5 inhibitors, and 5-alpha reductase inhibitors.
• Review of surgical options for refractory BPH.

Main Results:

• Transrectal ultrasonography is preferred for prostate sizing, especially before 5-alpha reductase inhibitor therapy or surgery.
• The International Prostate Symptom Score (IPSS) is the standard for symptom tracking.
• Self-management, Pygeum africanum, and beta-sitosterol show potential symptom improvement; saw palmetto is ineffective.
• Alpha blockers provide rapid relief; 5-alpha reductase inhibitors are beneficial for larger prostates (>30 mL) when used long-term, ideally with alpha blockers.
• Surgery is rarely required, with less invasive options available.

Conclusions:

• Comprehensive evaluation and tailored treatment plans are essential for managing LUTS in BPH.
• A combination of lifestyle modifications, appropriate pharmacotherapy, and shared decision-making for cancer screening optimizes patient outcomes.
• Less invasive treatments are increasingly preferred over traditional surgery for BPH.